Related Experiment Videos
Global standardisation of HbA1c
1Gleneagles Intan Medical Centre, Kuala Lumpur, Malaysia.
Insights
Standardizing hemoglobin A1c (HbA1c) assays is crucial for accurate diabetes management and complication risk prediction. The International Federation of Clinical Chemistry and Laboratory Medicine (IFCC) developed a global reference system for improved accuracy and comparability.
Area of Science:
- Clinical Chemistry
- Diabetology
- Laboratory Medicine
Background:
- Hemoglobin A1c (HbA1c) is vital for assessing glycemic control in diabetes patients.
- HbA1c levels predict the risk of diabetes-related complications, as shown by the DCCT trial.
- Standardization of HbA1c assays is essential for reliable and comparable results across laboratories.
Purpose of the Study:
- To highlight the importance of standardizing HbA1c assays.
- To introduce the International Federation of Clinical Chemistry and Laboratory Medicine (IFCC) global HbA1c reference system.
- To recommend reporting HbA1c results using both IFCC and NGSP standards, along with estimated average glucose (eAG).
Main Methods:
- Review of existing HbA1c standardization programs (NGSP, Sweden, Japan).
- Development of a global HbA1c reference system by the IFCC Working Group.
- Establishment of a relationship between IFCC-HbA1c, NGSP-HbA1c, and estimated average glucose (eAG).
Main Results:
- Existing standardization programs (NGSP, Sweden, Japan) use direct comparison methods (DCMs) and yield different results.
- The IFCC has developed a global reference system with significantly improved intra-assay and inter-assay precision.
- A strong correlation between eAG and HbA1c has been demonstrated, supporting dual reporting.
Conclusions:
- Standardized HbA1c measurements are critical for effective diabetes care and complication risk assessment.
- The IFCC global reference system offers improved accuracy and consistency for HbA1c testing.
- Reporting HbA1c in both IFCC units (mmol/mol Hb) and NGSP units (%) alongside eAG provides comprehensive glycemic information.
Abstract:
HbA1c is used for assessing glycaemic control in patients with diabetes. It is also used for treatment goals and as a target for therapeutic intervention. The Direct Control and Complications Trial in the USA showed that HbA1c can be used to predict the risk of complications. Hence, it is important for HbA1c assays to be standardised. The National Glycohemoglobin Standardization Program (NGSP) in the USA was formed in 1996 so that HbA1c results from different laboratories would be comparable to those reported in the DCCT study. There were also HbA1c standardisation programmes in Sweden and Japan. These three standardisation programmes are, in fact, direct comparison methods (DCMs), and yield different HbA1c results. In 1994, the International Federation of Clinical Chemistry and Laboratory Medicine (IFCC) established a Working Group on Standardisation of HbA1c. This working group has developed a global HbA1c reference system with very much improved intra-assay and inter-assay coefficients of variation. Recommendations have been made to report HbA1c results as IFCC-HbA1c values in SI units (mmol HbA1c/mol Hb) and NGSP-HbA1c (%) as well as estimated average glucose (eAG), once a tight relationship has been shown to exist between eAG and HbA1c.
Related Concept Videos
Hyperglycemia
Type II Diabetes Mellitus III: Clinical Manifestations and Diagnosis
Hypoglycemia
Diabetes Mellitus: Type 2 and Gestational
Testing a Claim about Standard Deviation
The hypothesis testing for the claim of population standard deviation (or variance) requires the data and samples to be random and unbiased. The population distribution also must be normal. There is no specific requirement on the sample size as the estimation is based on the chi-square distribution.
As a first step, the hypothesis (null and alternative) concerning the claim about...
Hypoglycemia and Glucagon